⌕
Hemab Therapeutics Holdings · COAG · Nasdaq
Tenet — · insufficient data
Compare
$39.86+1.81%At close
$39.86+0.71 (+1.81%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Hemab Therapeutics Holdings (COAG) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is COAG's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 11, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Hemab Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation…

COAG +1.8% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 13:31 ET
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript

Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript…

COAG +1.8% todayRead at source ↗
● MarketBeatNov 10, 2026 · 10:17 ET
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics NASDAQ: COAG has launched a pivotal Phase 3 trial of its experimental bleeding-disorder treatment sutacimig, moving its lead program into late-stage development as it prepares additional data presentat…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-003 reduced severe me…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

Hemab's first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:05 ETCOMPANY'S OWN WORDS
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the P…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation…

COAG +1.8% todayRead at source ↗
● Defense WorldOct 3, 2026 · 05:01 ET
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $32.60, but opened at $30.82. Hemab Therapeutics shares last trade…

COAG +1.8% todayRead at source ↗
● Defense WorldOct 2, 2026 · 06:21 ET
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) saw strong trading volume on Wednesday. 332,235 shares were traded during trading, a decline of 11% from the previous session's volume of 372,680 shares.…

COAG +1.8% todayRead at source ↗
● Defense WorldOct 1, 2026 · 06:15 ET
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat reports. One research anal…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireSep 24, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of successful launches…

COAG +1.8% todayRead at source ↗
● GlobeNewsWireSep 17, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare pro…

COAG +1.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT17−7.4%
AAPL8+0.4%
FOX6−2.9%
META6−2.1%

Article counts from the last market-wide feed page, across every symbol we track and not just COAG · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.